All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

267

Reset

267 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • paridiprubartPhase 22 trials

    PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)

  • PGN-EDODM1Phase 22 trials

    PepGen Inc · Myotonic Dystrophy 1

  • ProgerininPhase 22 trials

    PRG Science & Technology Co., Ltd. · Werner Syndrome, Hutchinson-Gilford Progeria Syndrome

  • R2R01Phase 22 trials

    River 2 Renal Corp. · Acute Kidney Injury, Hepatorenal Syndrome

  • R3R01Phase 22 trials

    River 3 Renal Corp. · Diabetic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis

  • REGN7544baloncibartPhase 22 trials

    Regeneron · Postural Orthostatic Tachycardia Syndrome (POTS), Sepsis-Induced Hypotension

  • rhu-pGSNrecombinant human gelsolin, Recombinant human plasma gelsolin pre-exposurePhase 22 trials

    BioAegis Therapeutics Inc. · Acute Respiratory Distress Syndrome, Infections, Decompression Sickness

  • rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • SAR447537Phase 22 trials

    Sanofi · Alpha 1-Antitrypsin Deficiency, Emphysema

  • SAT-3247Phase 22 trials

    Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD

  • TebapivatAG-946Phase 22 trials

    Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease

  • TTI-0102cysteamine-pantetheine disulfidePhase 22 trials

    Thiogenesis Therapeutics, Inc. · Nephropathic Cystinosis, Cystinosis, MELAS Syndrome

  • vilobelimabPhase 22 trials

    PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)

  • VNX001Phase 22 trials

    Vaneltix Pharma, Inc. · Interstitial Cystitis, Bladder Pain Syndrome

  • VX-670Phase 22 trials

    Vertex Pharmaceuticals · Myotonic Dystrophy Type 1 (DM1)

  • WVE-N531Phase 22 trials

    Wave Life Sciences USA, Inc. · Duchenne Muscular Dystrophy

  • AAVB-081Phase 21 trial

    AAVantgarde Bio Srl · Usher Syndrome, Type 1B

  • AB8939Phase 21 trial

    AB Science · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia

  • ABD-3001DIMATEPhase 21 trial

    Advanced BioDesign · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes

  • ACDN-01Phase 21 trial

    Ascidian Therapeutics, Inc · Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration

  • ALT-100Phase 21 trial

    Aqualung Therapeutics Corp. · Acute Respiratory Distress Syndrome (ARDS)

  • AMT-191Phase 21 trial

    UniQure Biopharma B.V. · Fabry Disease

  • AMXI-5001Phase 21 trial

    AtlasMedx, Incorporated · Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer

  • ARCT-810Phase 21 trial

    Arcturus Therapeutics, Inc. · OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD

  • ARD103Phase 21 trial

    ARCE Therapeutics, Inc. · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)

  • AT02Phase 21 trial

    Attralus, Inc. · Amyloidosis; Systemic

  • ATR 1072Phase 21 trial

    Atrium Therapeutics · Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic

  • ATSN-101Phase 21 trial

    Atsena Therapeutics Inc. · Leber Congenital Amaurosis, LCA, LCA1

  • ATV-1601Phase 21 trial

    Atavistik Bio, Inc · Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease

  • ATX-01Phase 21 trial

    ARTHEx Biotech S.L. · Myotonic Dystrophy 1

  • AV-001Phase 21 trial

    Vasomune Therapeutics, Inc. · Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia

  • AZD3632Phase 21 trial

    AstraZeneca · Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

  • BAY 3401016Phase 21 trial

    Bayer · Alport Syndrome

  • BBI-001Phase 21 trial

    Bond Biosciences · Hereditary Hemochromatosis

  • BEAM-302Phase 21 trial

    Beam Therapeutics Inc. · Alpha 1-Antitrypsin Deficiency

  • BFB-101AAV9-CBh-AP4B1Phase 21 trial

    BlackfinBio Ltd · HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis

  • BMN 307Phase 21 trial

    BioMarin · Phenylketonuria (PKU)

  • BW-20805Phase 21 trial

    Shanghai Argo Biopharmaceutical Co., Ltd. · Hereditary Angioedema (HAE)

  • CFI-400945Phase 21 trial

    Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

  • CLN-049Phase 21 trial

    Cullinan Therapeutics Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML

  • Ascendis Pharma Growth Disorders A/S · Achondroplasia

  • CSTI-500Phase 21 trial

    ConSynance Therapeutics · Prader-Willi Syndrome

  • CTH120Phase 21 trial

    Connecta Therapeutics, S.L. · Fragile X Syndrome (FXS), Fragile X Syndrome

  • CTO1681Phase 21 trial

    CytoAgents, Inc. · Cytokine Release Syndrome

  • CTX-712Phase 21 trial

    Chordia Therapeutics, Inc. · Acute Myeloid Leukemia, Myelodysplastic Syndromes

  • CTX460Phase 21 trial

    CRISPR Therapeutics · Alpha-1 Antitrypsin Deficiency (AATD)

  • DIAG723Phase 21 trial

    Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension

  • DNL126Phase 21 trial

    Denali Therapeutics Inc. · Mucopolysaccharidosis Type IIIA

  • DNL952Phase 21 trial

    Denali Therapeutics Inc. · Late-onset Pompe Disease

  • DT-168Phase 21 trial

    Design Therapeutics, Inc. · Fuchs Endothelial Corneal Dystrophy, Fuchs

NewerPage 4 of 6Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.